Omnicell, Inc.
Feb 7, 2003

Omnicell Announces Fourth Quarter and Year-End 2002 Financial Results

Product Backlog Grows $7 Million from the Third Quarter of 2002

PALO ALTO, Calif. — Feb. 7, 2003 — Omnicell, Inc. (NASDAQ: OMCL), a provider of solutions that improve patient care by enhancing the operational efficiency of healthcare organizations, today announced financial results for the fourth quarter and year ended December 31, 2002. The Company also announced a correction to its third quarter 2002 results and the adoption of a Stockholder Rights Plan.

Fourth Quarter and Year End 2002 Financial Results

For the fourth quarter of 2002, total revenue was $20.5 million compared to $24.4 million for the comparable period in 2001.

"We are pleased with our fourth quarter financial results," said Omnicell’s Chairman, President and CEO Randall A. Lipps. "Our revenue for the fourth quarter of 2002 was ahead of management’s guidance of $17 million to $19 million. Importantly, during the fourth quarter, we increased our product backlog by $7 million growing it to $28 million."

For the year ended December 31, 2002, total revenue was $87.7 million compared to $86.9 million in 2001.

The net loss for the fourth quarter of 2002 was $5 million or $(0.23) per share compared to net income of $1.4 million or $0.06 per share on a fully diluted basis in the fourth quarter of 2001. Included in the fourth quarter of 2002 was a restructuring charge of $1.7 million related to the previously announced headcount reduction and cost savings initiative as well as a one-time charge of $715,000 for the purchase of in-process research and development related to the acquisitions of the intellectual property of Medisafe and PharmacyCentral. These items represent approximately $(0.11) per share of the $(0.23) fourth quarter 2002 net loss per share.

For the year ended December 31, 2002, the net loss was $5 million or $(0.23) per share, compared to a net loss of $1.2 million or $(0.11) per share in 2001.

Omnicell’s cash balances as of December 31, 2002 were $21.5 million, compared to $21.3 million at September 30, 2002.

Fourth Quarter 2002 Business Progress

"During the quarter we made significant progress in building our product backlog, improving the efficiency of our operations, and integrating two product lines," commented Lipps. "We are particularly excited about the two new products we acquired in the last four months of 2002. These products extend our solutions from the hospital pharmacy to the patient’s bedside and clearly help to differentiate Omnicell in the marketplace. These additions to our product portfolio are mission critical in healthcare organizations because they comprehensively address the issue of patient safety. We believe that the strength of our product strategy, the improvement in our backlog, and the aggressive actions we have taken to improve our overall operations will enable Omnicell to return to profitability within the next few quarters."

In addition, Omnicell achieved the following in the fourth quarter of 2002:

Corrections to Third Quarter 2002 Financial Results

Omnicell records revenue based on completion of its installation obligation at the customer site. In January 2003, an error was discovered in the product revenue reported in the third quarter of 2002 relating to installations for one account, and this error has now been corrected. A total of $1.2 million of revenue was incorrectly reported as occurring in the third quarter. Of this amount, approximately $600,000 of product revenue, which had previously been reported in the third quarter, was actually installed in the fourth quarter and is now included in our fourth quarter 2002 financial results. The remainder of the revenue, or approximately $600,000, relates to product that had not yet been installed as of December 31, 2002, and was added to our product backlog as of the beginning of 2003. As a result of the correction, revenue for the third quarter is $17.9 million instead of the $19.1 million previously reported, and third quarter 2002 net loss is $3.5 million, or $(0.16) per share, compared to the $2.6 million net loss, or $(0.12) per share previously reported in our September 30, 2002 Form 10-Q. The fourth quarter and full year 2002 financial results accompanying this press release include these corrections. The Company will be filing an amended Form 10Q for the quarter ended September 30, 2002 reflecting the corrected results.

An independent investigation was conducted under the direction of the audit committee, on the basis of which it was determined that no additional adjustments to the Company’s financial statements were necessary. Management has implemented measures to ensure that similar errors do not occur in the future.

Stockholder Rights Plan Adopted

The Company also announced that its Board of Directors approved the adoption of a Stockholder Rights Plan under which all stockholders of record as of February 27, 2003 will receive rights to purchase shares of a new series of Preferred Stock.

The Rights Plan is designed to enable all Omnicell stockholders to realize the full value of their investment and to provide for fair and equal treatment for all stockholders in the event that an unsolicited attempt is made to acquire Omnicell. The adoption of the Rights Plan is intended as a means to guard against abusive takeover tactics and is not in response to any particular proposal or event.

The rights will be distributed as a non-taxable dividend and will expire in ten years from the record date. The rights will be exercisable only if a person or group acquires 15 percent or more of the Common Stock. If a person acquires 15 percent or more of Omnicell’s Common Stock, all rights holders except the buyer will be entitled to acquire Omnicell Common Stock at a discount. Sutter Hill Ventures and ABS Capital Partners and their respective affiliated entities will be exempt from the Rights Plan, unless they acquire beneficial ownership of 17.5 percent or 22.5 percent or more, respectively, of Omnicell’s Common Stock. The effect will be to discourage acquisitions of more than 15 percent of Omnicell’s Common Stock without negotiations with the Board.

The rights will trade with Omnicell’s Common Stock, unless and until they are separated upon the occurrence of certain future events. The rights distribution is not taxable to the stockholders. Omnicell’s Board of Directors may terminate the Rights Plan at any time or redeem the rights prior to the time the rights are triggered. Additional details regarding the Rights Plan will be outlined in a summary to be mailed to all stockholders following the record date.

Conference Call Details

Management will discuss fourth quarter results and provide an outlook for business going forward today at 8:45 a.m. ET. Investors and analysts interested in joining the conference call may log on to the Webcast at www.omnicell.com or access the call by dialing 800-240-2430 (domestic) or 303-262-2127 (international) approximately 10 minutes prior to the scheduled start. A replay of the call will be available from 10:30 a.m. ET on February 7 through 11:59 p.m. ET on Feb. 14. Dialing 800-405-2236 (domestic) or 303-590-3000 (international) and entering the passcode 518803# for both numbers will access the call replay.

About Omnicell

Established in 1992, Omnicell (NASDAQ: OMCL) provides solutions that improve patient care by enhancing the operational efficiency of healthcare organizations. Addressing the medication management and supply chain areas, Omnicell's medication and supply dispensing systems and decision support tools enable healthcare facilities to decrease costs, operate more efficiently, and reduce medication errors. For more information, visit www.omnicell.com.

To the extent any statements contained in this release deal with information that is not historical, these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events outside Omnicell’s control and are subject to various risk factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. The risk factors are described in the Company’s Securities and Exchange Commission filings and include, without limitation, the continued growth and acceptance of our products and services and the continued growth of the clinical automation and workflow automation market generally, the potential of increasing competition, the ability of the Company to achieve profitability in the next few quarters, grow product backlog, retain key personnel, cut expenses, develop new products and integrate acquired products or intellectual property in a timely and cost-effective manner, and improve sales productivity. Prospective investors are cautioned not to place undue reliance on forward-looking statements.

 

 

(see detailed financial results next page)

 

 

 

 

OMNICELL, INC.

SELECTED FINANCIAL INFORMATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

 

 

 

 

 

 

Three Months Ended

December 31,

 

Twelve Months Ended

December 31,

 

 

 

 

 

 

 

 

 

2002

 

2001

 

2002

 

2001

Revenue:

 

 

 

 

 

 

 

 

 

Product revenue

$16,425

 

$20,918

 

$72,834

 

$75,501

 

Service and other revenue

4,042

 

3,477

 

14,856

 

11,400

Total revenue

 

20,467

 

24,395

 

87,690

 

86,901

Costs and expenses:

 

 

 

 

 

 

 

 

Cost of product revenues

7,518

 

7,762

 

30,308

 

26,745

 

Cost of service and other revenues

1,306

 

1,245

 

6,110

 

6,022

Total cost of revenues

8,824

 

9,007

 

36,418

 

32,767

Gross margin

 

11,643

 

15,388

 

51,272

 

54,134

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

2,681

 

2,553

 

9,970

 

11,031

 

Selling, general and administrative

11,902

 

11,703

 

44,767

 

43,683

 

Restructuring

 

1,723

 

(150)

 

1,723

 

(150)

 

Purchased in-process research and development

715

 

0

 

715

 

0

Total operating expenses

17,021

 

14,106

 

57,175

 

54,564

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

(5,378)

 

1,282

 

(5,903)

 

(430)

 

 

 

 

 

 

 

 

 

 

 

Other income and (expense)

385

 

201

 

875

 

(577)

 

 

 

 

 

 

 

 

 

 

 

Income (loss) before provision for income taxes

(4,993)

 

1,483

 

(5,028)

 

(1,007)

 

 

 

 

 

 

 

 

 

 

 

Provision for income taxes

20

 

85

 

10

 

160

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

($5,013)

 

$1,398

 

($5,038)

 

($1,167)

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share - basic

($0.23)

 

$0.07

 

($0.23)

 

($0.11)

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share - diluted

($0.23)

 

$0.06

 

($0.23)

 

($0.11)

 

 

 

 

 

 

 

 

 

 

 

Shares used in computing net income (loss)

21,992

 

21,437

 

21,725

 

10,312

per share - basic

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in computing net income (loss)

21,992

 

22,795

 

21,725

 

10,312

per share - diluted

 

 

 

 

 

 

 

 

 

SUMMARY BALANCE SHEET

 

December 31,

December 31,

 

 

 

 

 

2002

 

2001

 

 

 

 

 

 

 

 

(Note 1)

 

Cash, cash equivalents and short-term marketable securities

21,485

 

23,839

 

Trade receivables, net

 

10,644

 

18,167

 

Inventory, net

 

 

12,741

 

12,702

 

Other current assets

 

3,575

 

4,803

 

Property and equipment, net

 

5,026

 

5,384

 

Other assets

 

 

12,071

 

7,219

 

Total assets

 

 

65,542

 

72,114

 

 

 

 

 

 

 

 

 

 

Deferred service revenue

 

11,598

 

8,009

 

Deferred gross profit

 

18,008

 

24,790

 

Other current liabilities

 

18,867

 

19,351

 

Long-term obligations

 

763

 

363

 

Stockholders' equity

 

16,306

 

19,601

 

Total liabilities and stockholders' equity

 

65,542

 

72,114

 

(Note 1 - December 31, 2001 amounts derived from the audited financial statements at that date. 

Certain amounts have been reclassified to conform to current period presentation.)